HIKAL
|
The Current P/E Ratio of HIKAL is 47.39.
Share Price | ₹243.3 | Oct 21,2025 |
Market Cap | ₹2,999.9 Cr | |
Earnings-TTM | ₹63.3 Cr | TTM-Consolidated Results |
Price/Earnings | 47.39x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of HIKAL
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹2,999.9 Cr] as on Oct 21,2025
(/) Earnings [ ₹63.3 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 47.39x ]
Thus, for HIKAL , the investors are currently willing to pay 47.39 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of HIKAL !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of HIKAL over the last five years.
Historical PE (Price/Earnings) ratio chart of HIKAL
PE Ratio Performance Analysis for HIKAL
- HIKAL 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 37.99x.
- HIKAL 's operated at median p/e ratio of 44.34x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, HIKAL 's p/e ratio peaked in Mar2025 at 54.42x.
- HIKAL 's p/e ratio hit its five-year low in Mar2021 of 13.29x.
How does HIKAL 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
HIKAL | 63.30 | 47.39 | 2,999.9 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 10,411.50 | 38.95 | 405,560.0 |
DIVIS LABORATORIES LTD | 2,306.00 | 75.90 | 175,033.0 |
CIPLA LTD | 5,406.81 | 24.86 | 134,400.0 |
TORRENT PHARMACEUTICALS LTD | 2,002.00 | 60.69 | 121,507.0 |
DR REDDYS LABORATORIES LTD | 5,726.70 | 18.79 | 107,628.0 |
MANKIND PHARMA LTD | 1,905.51 | 53.00 | 100,992.0 |
ZYDUS LIFESCIENCES LTD | 4,637.80 | 21.69 | 100,613.0 |
LUPIN LTD | 3,722.18 | 23.85 | 88,766.9 |
AUROBINDO PHARMA LTD | 3,417.93 | 18.71 | 63,946.3 |
ABBOTT INDIA LTD | 1,452.29 | 44.27 | 64,293.4 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs HIKAL 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.71x |
Max industry PE | 75.90x |
Median industry PE | 38.95x |
Average industry PE | 38.92x |
You may also like the below Video Courses